Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Nucl Med
    November 2024
  1. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
    PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
    J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
    >> Share

  2. WENZEL M, Koll F, Hoeh B, Humke C, et al
    Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
    >> Share

  3. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
    SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
    >> Share

  4. ZAGNI F, Vetrone L, Farolfi A, Vadala M, et al
    Feasibility of (177)Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer.
    J Nucl Med. 2024 Nov 7:jnumed.124.268062. doi: 10.2967/jnumed.124.268062.
    >> Share

  5. SAIDI A, Stallons TA, Wong AG, Torgue JJ, et al
    Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.
    J Nucl Med. 2024;65:1769-1775.
    >> Share

    October 2024
  6. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
    Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
    J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
    >> Share

  7. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
    FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
    >> Share

  8. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
    Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
    >> Share

  9. MUNIZ M, Sartor O, Orme JJ, Koch RM, et al
    Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2024 Oct 30:jnumed.124.268277. doi: 10.2967/jnumed.124.268277.
    >> Share

  10. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    >> Share

  11. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    >> Share

    September 2024
  12. MURTHY V, Voter AF, Nguyen K, Allen-Auerbach M, et al
    Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
    J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816.
    >> Share

  13. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    >> Share

  14. POULIOT F, Saad F, Rousseau E, Richard PO, et al
    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
    >> Share

  15. GAFITA A, Voter A, Shesadri S, Spitz A, et al
    Initial Experience with [(177)Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
    J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723.
    >> Share

  16. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
    Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
    J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
    >> Share

  17. POSCHENRIEDER A, Taleska J, Schaetz L
    (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
    J Nucl Med. 2024;65:1340-1342.
    >> Share

  18. BELGE BILGIN G, Burkett BJ, Bilgin C, Orme JJ, et al
    Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.
    J Nucl Med. 2024;65:1402-1408.
    >> Share

    August 2024
  19. WONG AJN, Ko HS, Hofman MS
    Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics Through the Lens of RELAINCE.
    J Nucl Med. 2024 Aug 29:jnumed.124.267924. doi: 10.2967/jnumed.124.267924.
    >> Share

  20. THIN P, Hotta M, Gafita A, Grogan T, et al
    Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
    >> Share

  21. HO KV, Tatum DS, Watkinson L, Carmack T, et al
    Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
    >> Share

  22. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
    [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
    J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
    >> Share

  23. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
    Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
    >> Share

  24. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
    (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
    J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
    >> Share

  25. LI S, Nguyen A, Counter W, John NC, et al
    Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
    >> Share

  26. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
    Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
    >> Share

  27. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
    Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
    J Nucl Med. 2024;65:1210-1216.
    >> Share

    July 2024
  28. DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al
    Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658.
    >> Share

  29. AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al
    Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477.
    >> Share

  30. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
    (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
    J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
    >> Share

  31. BUTEAU JP, Kostos L, Alipour R, Jackson P, et al
    Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [(161)Tb]Tb-PSMA-I&T.
    J Nucl Med. 2024 Jul 11:jnumed.124.267650. doi: 10.2967/jnumed.124.267650.
    >> Share

  32. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
    Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
    >> Share

  33. RATHKE H, Winter E, Bruchertseifer F, Rohrich M, et al
    Deescalated (225)Ac-PSMA-617 Versus (177)Lu/(225)Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
    J Nucl Med. 2024;65:1057-1063.
    >> Share

    June 2024
  34. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
    Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
    J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
    >> Share

  35. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
    Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
    J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
    >> Share

  36. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
    A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
    >> Share

  37. PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al
    Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of (99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450.
    >> Share

  38. SEIFERT R, Telli T, Lapa C, Desaulniers M, et al
    Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German Multicenter Study.
    J Nucl Med. 2024;65:909-916.
    >> Share

    May 2024
  39. PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al
    A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416.
    >> Share

  40. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    >> Share

  41. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    >> Share

  42. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    >> Share

  43. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    >> Share

  44. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
    Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
    J Nucl Med. 2024;65:735-739.
    >> Share

    April 2024
  45. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    >> Share

  46. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    >> Share

  47. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    >> Share

  48. HUANG YY, Lin TC, Yang SH, Lai LS, et al
    [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
    J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533.
    >> Share

  49. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    >> Share

  50. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    >> Share

  51. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
    Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
    J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
    >> Share

  52. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
    Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2024;65:566-572.
    >> Share

    March 2024
  53. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    >> Share

  54. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    >> Share

  55. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
    Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
    J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
    >> Share

    February 2024
  56. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    >> Share

  57. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    >> Share

  58. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    >> Share

  59. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    >> Share

  60. MAURER T, Thomas C, Hadaschik B
    The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?
    J Nucl Med. 2024 Feb 15:jnumed.123.267187. doi: 10.2967/jnumed.123.267187.
    >> Share

  61. KUMAR S, Crumbaker M, Emmett L
    Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:333-334.
    >> Share

  62. ASKARI E, Harsini S
    Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:332-333.
    >> Share

    January 2024
  63. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    >> Share

  64. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    >> Share

  65. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    >> Share

  66. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    >> Share

  67. RAVI KUMAR AS, Hofman MS
    Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
    J Nucl Med. 2024;65:85-86.
    >> Share

  68. STEINHELFER L, Lunger L, Cala L, Pfob CH, et al
    Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2024;65:79-84.
    >> Share

    December 2023
  69. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    >> Share

  70. BENABDALLAH N, Lu P, Abou DS, Zhang H, et al
    Beyond Average: alpha-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 14:jnumed.123.266571. doi: 10.2967/jnumed.123.266571.
    >> Share

  71. JADVAR H
    Sequential and Combination Therapies of (223)RaCl(2) and Prostate-Specific Membrane Antigen Radioligand Therapy.
    J Nucl Med. 2023;64:1932-1933.
    >> Share

    November 2023
  72. EMMETT L, Papa N, Counter W, Calais J, et al
    Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
    >> Share

  73. WANG F, Liu C, Vidal I, Mana-Ay M, et al
    Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
    J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
    >> Share

  74. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
    Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
    J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
    >> Share

  75. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
    Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
    J Nucl Med. 2023 Nov 30:jnumed.123.265448. doi: 10.2967/jnumed.123.265448.
    >> Share

  76. SARTOR O, Ledet E, Huang M, Schwartz J, et al
    Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
    J Nucl Med. 2023;64:1721-1725.
    >> Share

    October 2023
  77. RAHBAR K, Essler M, Eiber M, la Fougere C, et al
    (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
    J Nucl Med. 2023 Oct 12:jnumed.123.266125. doi: 10.2967/jnumed.123.266125.
    >> Share

  78. MEYER C, Stuparu A, Lueckerath K, Calais J, et al
    Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer.
    J Nucl Med. 2023 Oct 5:jnumed.123.265433. doi: 10.2967/jnumed.123.265433.
    >> Share

  79. TSCHAN VJ, Busslinger SD, Bernhardt P, Grundler PV, et al
    Albumin-Binding and Conventional PSMA Ligands in Combination with (161)Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
    J Nucl Med. 2023;64:1625-1631.
    >> Share

  80. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:1632-1637.
    >> Share

  81. GRAVES SA
    Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2023;64:1567-1569.
    >> Share

    September 2023
  82. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
    PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
    >> Share

  83. RINSCHEID A, Gable A, Wienand G, Pfob C, et al
    An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970.
    >> Share

  84. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
    Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
    J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
    >> Share

  85. SATAPATHY S, Mittal BR, Sood A, Das CK, et al
    [(177)Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.
    J Nucl Med. 2023 Sep 14:jnumed.123.266141. doi: 10.2967/jnumed.123.266141.
    >> Share

  86. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
    Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
    J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
    >> Share

  87. MURTHY V, Gafita A, Thin P, Nguyen K, et al
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
    J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
    >> Share

  88. KUMAR S, Crumbaker M, Harvey C, Pathmanandavel S, et al
    The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2023;64:1412-1416.
    >> Share

  89. MURTHY V, Allen-Auerbach M, Lam R, Owen D, et al
    PSMA-Negative Lesion Progression Under (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2023;64:1502-1503.
    >> Share

  90. HOPE TA, Antonarakis ES, Bodei L, Calais J, et al
    SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-PSMA-617 Radionuclide Therapy.
    J Nucl Med. 2023;64:1417-1423.
    >> Share

    August 2023
  91. ZHANG J, Kang F, Gao J, Jiao J, et al
    A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study.
    J Nucl Med. 2023 Aug 31:jnumed.122.265001. doi: 10.2967/jnumed.122.265001.
    >> Share

  92. GRKOVSKI M, O'Donoghue JA, Imber BS, Andl G, et al
    Lesion Dosimetry for [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
    J Nucl Med. 2023 Aug 31:jnumed.123.265763. doi: 10.2967/jnumed.123.265763.
    >> Share

  93. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
    PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
    J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
    >> Share

  94. HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al
    Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
    J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953.
    >> Share

  95. ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al
    Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546.
    >> Share

  96. EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al
    Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
    J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025.
    >> Share

  97. HOPE TA, Benz M, Jiang F, Thompson D, et al
    Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
    J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916.
    >> Share

  98. DE JONG AC, Segbers M, Ling SW, Graven LH, et al
    (68)Ga-PSMA PET/CT for Response Evaluation of (223)Ra Treatment in Metastatic Prostate Cancer.
    J Nucl Med. 2023 Aug 3:jnumed.123.265489. doi: 10.2967/jnumed.123.265489.
    >> Share

    July 2023
  99. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523.
    >> Share

  100. CHEN M, Fu Y, Peng S, Zang S, et al
    The Association Between [(68)Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy.
    J Nucl Med. 2023 Jul 20:jnumed.122.265368. doi: 10.2967/jnumed.122.265368.
    >> Share

  101. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771.
    >> Share

  102. DUIN JJ, de Barros HA, Donswijk ML, Schaake EE, et al
    The Diagnostic Value of the Sentinel Node Procedure to Detect Occult Lymph Node Metastases in PSMA PET/CT Node-Negative Prostate Cancer Patients.
    J Nucl Med. 2023 Jul 6:jnumed.123.265556. doi: 10.2967/jnumed.123.265556.
    >> Share

  103. STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al
    Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
    J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770.
    >> Share

  104. CARDINALE J, Giesel FL, Wensky C, Rathke HG, et al
    PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen.
    J Nucl Med. 2023;64:1069-1075.
    >> Share

    June 2023
  105. HAGENS MJ, Luining WI, Jager A, Donswijk ML, et al
    The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer.
    J Nucl Med. 2023 Jun 29:jnumed.122.265205. doi: 10.2967/jnumed.122.265205.
    >> Share

  106. PALMEDO H, Ahmadzadehfar H, Eschmann S, Niesen A, et al
    Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study.
    J Nucl Med. 2023 Jun 29:jnumed.123.265557. doi: 10.2967/jnumed.123.265557.
    >> Share

  107. AH-THIANE L, Ferrer L, Rousseau C
    PSMA Is Not Specific to Prostate Cancer.
    J Nucl Med. 2023 Jun 22:jnumed.123.265720. doi: 10.2967/jnumed.123.265720.
    >> Share

  108. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Reply: PSMA Is Not Specific to Prostate Cancer.
    J Nucl Med. 2023 Jun 22:jnumed.123.265921. doi: 10.2967/jnumed.123.265921.
    >> Share

  109. TAUBER R, Knorr K, Retz M, Rauscher I, et al
    Safety and Efficacy of [(177)Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
    J Nucl Med. 2023 Jun 15:jnumed.122.265259. doi: 10.2967/jnumed.122.265259.
    >> Share

  110. KARIMZADEH A, Heck M, Tauber R, Solaris E, et al
    The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    J Nucl Med. 2023 Jun 8:jnumed.122.265346. doi: 10.2967/jnumed.122.265346.
    >> Share

  111. HARTRAMPF PE, Mihatsch PW, Seitz AK, Solnes LB, et al
    Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
    J Nucl Med. 2023 Jun 8:jnumed.122.265379. doi: 10.2967/jnumed.122.265379.
    >> Share

    May 2023
  112. BERLINER C, Steinhelfer L, Chantadisai M, Kroenke M, et al
    Delayed Imaging Improves Lesion Detectability in [(99m)Tc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
    J Nucl Med. 2023 May 25:265252. doi: 10.2967/jnumed.122.265252.
    >> Share

  113. KUO PH, Yoo DC, Avery R, Seltzer M, et al
    A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy.
    J Nucl Med. 2023 May 25:265077. doi: 10.2967/jnumed.122.265077.
    >> Share

  114. BOBBA KN, Bidkar AP, Meher N, Fong C, et al
    Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac alpha-Radiotherapeutics.
    J Nucl Med. 2023 May 18:265355. doi: 10.2967/jnumed.122.265355.
    >> Share

  115. SATAPATHY S, Sahoo RK, Bal C
    [(177)Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naive Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2023 May 11:265414. doi: 10.2967/jnumed.123.265414.
    >> Share

  116. EVANGELISTA L
    PSMA PET/CT and Therapy Response Evaluation in Metastatic Prostate Cancer: Is It Time to Surpass the Old Way?
    J Nucl Med. 2023 May 11:265308. doi: 10.2967/jnumed.122.265308.
    >> Share

  117. FEUERECKER B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, et al
    Clinical Translation of Targeted alpha-Therapy: An Evolution or a Revolution?
    J Nucl Med. 2023;64:685-692.
    >> Share

  118. BROSCH-LENZ J, Delker A, Volter F, Unterrainer LM, et al
    Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy.
    J Nucl Med. 2023;64:767-774.
    >> Share

    April 2023
  119. KESLER M, Cohen D, Levine C, Sarid D, et al
    Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
    J Nucl Med. 2023 Apr 28:jnumed.122.265371. doi: 10.2967/jnumed.122.265371.
    >> Share

  120. GRAEF J, Bluemel S, Brenner W, Amthauer H, et al
    [(177)Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement.
    J Nucl Med. 2023 Apr 28:jnumed.122.264850. doi: 10.2967/jnumed.122.264850.
    >> Share

  121. MORRIS MJ, Calais J, Czernin J
    Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin.
    J Nucl Med. 2023 Apr 13:265684. doi: 10.2967/jnumed.123.265684.
    >> Share

    March 2023
  122. HOTTA M, Gafita A, Murthy V, Benz MR, et al
    PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [(177)Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
    J Nucl Med. 2023 Mar 30:jnumed.122.265242. doi: 10.2967/jnumed.122.265242.
    >> Share

  123. RAVI P, Whelpley B, Kelly E, Wolanski A, et al
    Clinical Implementation of (177)Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
    J Nucl Med. 2023;64:349-350.
    >> Share

    February 2023
  124. SONNI I, Dal Pra A, O'Connell DP, Ells Z, et al
    PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines.
    J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025.
    >> Share

  125. TRAPP C, Oliinyk D, Rogowski P, Von Bestenbostel R, et al
    An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients.
    J Nucl Med. 2023 Feb 2:jnumed.122.265159. doi: 10.2967/jnumed.122.265159.
    >> Share

    January 2023
  126. AL JALALI V, Wasinger G, Rasul S, Grubmueller B, et al
    Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naive prostate cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264981. doi: 10.2967/jnumed.122.264981.
    >> Share

  127. GUDENKAUF LM, Chavez M, Maconi ML, Geiss C, et al
    Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy.
    J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946.
    >> Share

  128. CALDERONI L, Maietti E, Farolfi A, Mei R, et al
    Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    J Nucl Med. 2023 Jan 12:jnumed.122.264964. doi: 10.2967/jnumed.122.264964.
    >> Share

    December 2022
  129. LUNGER L, Chantadisai M, Karimzadeh A, Rauscher I, et al
    The prognostic role of (68)Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy.
    J Nucl Med. 2022 Dec 29:jnumed.122.264962. doi: 10.2967/jnumed.122.264962.
    >> Share

  130. SEIFERT R, Telli T, Hadaschik B, Fendler WP, et al
    Is (18)F-FDG PET needed to assess (177)Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis.
    J Nucl Med. 2022 Dec 15:jnumed.122.264741. doi: 10.2967/jnumed.122.264741.
    >> Share

  131. SEIFERT R, Telli T, Opitz M, Barbato F, et al
    Non-specific PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scan and MRI triple validation in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Dec 2:jnumed.118.215434. doi: 10.2967/jnumed.118.215434.
    >> Share

  132. PERERA M, Morris MJ
    From Concept to Regulatory Drug Approval: Lessons for Theranostics.
    J Nucl Med. 2022;63:1793-1801.
    >> Share

  133. HERRMANN K, Giovanella L, Santos A, Gear J, et al
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    J Nucl Med. 2022;63:1836-1843.
    >> Share

    November 2022
  134. OLIVIER P, Giraudet AL, Skanjeti A, Merlin C, et al
    Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264743. doi: 10.2967/jnumed.122.264743.
    >> Share

  135. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264448. doi: 10.2967/jnumed.122.264448.
    >> Share

  136. FRAGOSO COSTA P, Pullen L, Kesch C, Krafft U, et al
    F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.264670. doi: 10.2967/jnumed.122.264670.
    >> Share

  137. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264783. doi: 10.2967/jnumed.122.264783.
    >> Share

  138. WANG G, Zang J, Jiang Y, Liu Q, et al
    A single-arm, low-dose, prospective study of (177)Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264857. doi: 10.2967/jnumed.122.264857.
    >> Share

  139. LAWAL IO, Adediran OA, Jani AB, Goyal S, et al
    Differences in Failure-free Survival Post Salvage Radiotherapy Guided by Conventional Imaging Versus (18)F-fluciclovine PET/CT in Post-prostatectomy Patients: a Post-hoc Sub-stratification Analysis of the EMPIRE-1 Trial.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264832. doi: 10.2967/jnumed.122.264832.
    >> Share

  140. JADVAR H, Abreu AL, Ballas LK, Quinn DI, et al
    Oligometastatic Prostate Cancer: Current Status and Future Challenges.
    J Nucl Med. 2022;63:1628-1635.
    >> Share

    October 2022
  141. COOK GJR, Wong WL, Sanghera B, Mangar S, et al
    Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castrate resistant prostate cancer.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264296. doi: 10.2967/jnumed.122.264296.
    >> Share

  142. RAHBAR K, Essler M, Pabst KM, Eiber M, et al
    Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264456. doi: 10.2967/jnumed.122.264456.
    >> Share

  143. KIND F, Eder AC, Jilg CA, Hartrampf P, et al
    Prognostic value of tumor volume assessment on PSMA PET after (177)Lu-PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264489. doi: 10.2967/jnumed.122.264489.
    >> Share

  144. PHELPS TE, Harmon SA, Mena E, Lindenberg L, et al
    Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264334. doi: 10.2967/jnumed.122.264334.
    >> Share

  145. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal IO, et al
    mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
    J Nucl Med. 2022;63:1496-1502.
    >> Share

    September 2022
  146. KARIMZADEH A, Heck M, Tauber R, Knorr K, et al
    (177)Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264402. doi: 10.2967/jnumed.122.264402.
    >> Share

  147. JOHN N, Pathmanandavel S, Crumbaker M, Counter W, et al
    (177)Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
    J Nucl Med. 2022 Sep 8. pii: jnumed.122.264677. doi: 10.2967/jnumed.122.264677.
    >> Share

  148. SCHOLLHAMMER R, Robert G, Asselineau J, Yacoub M, et al
    Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.263889. doi: 10.2967/jnumed.122.263889.
    >> Share

  149. BELLAVIA MC, Patel RB, Anderson CJ
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264373. doi: 10.2967/jnumed.122.264373.
    >> Share

  150. KLOSE JM, Wosniack J, Iking J, Staniszewska M, et al
    Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.
    J Nucl Med. 2022;63:1357-1363.
    >> Share

  151. COSTA PF, Fendler WP, Herrmann K, Sandach P, et al
    Radiation Protection and Occupational Exposure on (68)Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy.
    J Nucl Med. 2022;63:1349-1356.
    >> Share

    August 2022
  152. HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
    Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
    J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
    >> Share

  153. PATHMANANDAVEL S, Crumbaker M, Ho B, Yam AO, et al
    Evaluation of (177)Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264398. doi: 10.2967/jnumed.122.264398.
    >> Share

  154. BEYER T, Czernin J, Freudenberg LS, Giesel F, et al
    A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS.
    J Nucl Med. 2022 Aug 11. pii: jnumed.122.264298. doi: 10.2967/jnumed.122.264298.
    >> Share

    July 2022
  155. DERLIN T, Widjaja L, Werner RA, Bengel FM, et al
    (177)Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.264293. doi: 10.2967/jnumed.122.264293.
    >> Share

  156. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
    Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
    >> Share

  157. HOFLING AA, Fotenos AF, Niu G, Fallah J, et al
    Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264299. doi: 10.2967/jnumed.122.264299.
    >> Share

  158. PAINDELLI C, Casarin S, Wang F, Diaz-Gomez L, et al
    Enhancing (223)Ra Treatment Efficacy by Anti-beta1 Integrin Targeting.
    J Nucl Med. 2022;63:1039-1045.
    >> Share

    June 2022
  159. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
    The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
    >> Share

  160. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    >> Share

  161. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    >> Share

  162. SARTOR O, Herrmann K
    Prostate Cancer Treatment: (177)Lu-PSMA-617 Considerations, Concepts, and Limitations.
    J Nucl Med. 2022;63:823-829.
    >> Share

  163. JADVAR H
    The VISION Forward: Recognition and Implication of PSMA-/(18)F-FDG+ mCRPC.
    J Nucl Med. 2022;63:812-815.
    >> Share

    May 2022
  164. SARTOR O
    Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
    >> Share

  165. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
    Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
    >> Share

  166. MORADI F, Duan H, Song H, Davidzon GA, et al
    (68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
    J Nucl Med. 2022 May 5. pii: jnumed.122.263897. doi: 10.2967/jnumed.122.263897.
    >> Share


  167. FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:13N.
    >> Share

    April 2022
  168. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
    Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
    >> Share

  169. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
    Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
    >> Share

  170. KROENKE M, Schweiger L, Horn T, Haller B, et al
    Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
    >> Share

    March 2022
  171. EMMETT LM, Papa N, Buteau J, Ho B, et al
    The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
    >> Share

  172. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
    (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
    >> Share

  173. HOTTA M, Gafita A, Czernin J, Calais J, et al
    Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
    >> Share

  174. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
    >> Share

  175. GONDOPUTRO W, Scheltema MJ, Blazevski A, Doan P, et al
    Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263743. doi: 10.2967/jnumed.121.263743.
    >> Share

    February 2022
  176. WU WY, Yu F, Zhang PJ, Bu T, et al
    (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
    >> Share


  177. FDA Approves New (68)Ga Kit for Prostate Cancer PET.
    J Nucl Med. 2022;63:26N.
    >> Share

  178. SARTOR O
    Reply: A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324-325.
    >> Share

  179. SCHIAVOM DUARTE P
    A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324.
    >> Share

  180. MEASE RC, Kang CM, Kumar V, Banerjee SR, et al
    An Improved (211)At-Labeled Agent for PSMA-Targeted alpha-Therapy.
    J Nucl Med. 2022;63:259-267.
    >> Share

    January 2022
  181. WURZER A, Kunert JP, Fischer S, Felber V, et al
    Synthesis and Preclinical Evaluation of (177)Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263371. doi: 10.2967/jnumed.121.263371.
    >> Share

  182. KORSEN JA, Kalidindi TM, Khitrov S, Samuels ZV, et al
    Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263221. doi: 10.2967/jnumed.121.263221.
    >> Share

  183. SUTERA P, Phillips RM, Deek M, Ozyigit G, et al
    The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263684. doi: 10.2967/jnumed.121.263684.
    >> Share

  184. NG M, Guerrieri M, Wong LM, Taubman K, et al
    The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
    >> Share

  185. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    >> Share

  186. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    >> Share

    December 2021
  187. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
    Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
    >> Share

  188. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
    Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
    >> Share

    November 2021
  189. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    >> Share

  190. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    >> Share

  191. SRINIVAS S, Iagaru A
    To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
    J Nucl Med. 2021;62:1487-1488.
    >> Share

    October 2021
  192. MIYAHIRA AK, Soule HR
    The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
    >> Share

  193. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    >> Share

  194. CALAIS J, Czernin J, Thin P, Gartmann J, et al
    Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
    J Nucl Med. 2021;62:1447-1456.
    >> Share

  195. NOTNI J
    PSMA-Targeted Therapeutics: A Tale About Law and Economics.
    J Nucl Med. 2021;62:1482.
    >> Share

  196. EDER AC, Schafer M, Schmidt J, Bauder-Wust U, et al
    Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.
    J Nucl Med. 2021;62:1461-1467.
    >> Share

    September 2021
  197. FEUERECKER B, Chantadisai M, Allmann A, Tauber R, et al
    Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262671. doi: 10.2967/jnumed.121.262671.
    >> Share

  198. LEE DY, Kim YI
    Effects of (225)Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262017. doi: 10.2967/jnumed.121.262017.
    >> Share

  199. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    >> Share

  200. WAHL RL
    Progress in Prostate Cancer Theranostics.
    J Nucl Med. 2021;62:11N.
    >> Share

  201. BRENNER W, Strobel J, Prasad V
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    J Nucl Med. 2021;62:1242-1243.
    >> Share

    August 2021
  202. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    >> Share

  203. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    >> Share

  204. SANDHU S, Guo C, Hofman MS
    Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.243295. doi: 10.2967/jnumed.120.243295.
    >> Share

  205. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    >> Share


  206. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    >> Share


  207. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    >> Share

  208. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    >> Share

  209. YUSUFI N, Wurzer A, Herz M, D'Alessandria C, et al
    Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T.
    J Nucl Med. 2021;62:1106-1111.
    >> Share

  210. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    >> Share

  211. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    >> Share

    July 2021
  212. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    >> Share

  213. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    >> Share

  214. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
    (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
    >> Share

  215. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    >> Share

  216. BENARD F, Bratanovic IJ
    A Novel Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor Positive Prostate Cancer.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.257758. doi: 10.2967/jnumed.120.257758.
    >> Share

  217. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
    Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
    >> Share

    June 2021
  218. SARTOR AO, la Fougere C, Essler M, Ezziddin S, et al
    Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262240. doi: 10.2967/jnumed.121.262240.
    >> Share

  219. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    >> Share

  220. MCINNES LE, Cullinane C, Roselt PD, Jackson S, et al
    Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with (67)Cu.
    J Nucl Med. 2021;62:829-832.
    >> Share

    May 2021
  221. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    >> Share

  222. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    >> Share

  223. CALAIS J, Gafita A, Eiber MR, Armstrong WR, et al
    Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
    J Nucl Med. 2021 May 20. pii: jnumed.121.261982. doi: 10.2967/jnumed.121.261982.
    >> Share

  224. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    >> Share

  225. TREIBER H, Koenig A, Neesse A, Richter A, et al
    Liver enzyme elevation after (177)Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer.
    J Nucl Med. 2021 May 14. pii: jnumed.120.258533. doi: 10.2967/jnumed.120.258533.
    >> Share

  226. ZACHERL MJ, Gildehaus FJ, Mittlmeier L, Boning G, et al
    First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients.
    J Nucl Med. 2021;62:669-674.
    >> Share

    April 2021
  227. FENDLER WP, Farolfi A
    REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.
    >> Share

  228. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
    Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
    >> Share

  229. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    >> Share

  230. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
    The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.262104. doi: 10.2967/jnumed.121.262104.
    >> Share

    March 2021
  231. RITT P, Jobic C, Beck M, Schmidkonz C, et al
    Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2021;62:379-385.
    >> Share

    November 2020
  232. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
    Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
    >> Share

    October 2020
  233. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
    Measurement of PET Quantitative Bias In Vivo.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
    >> Share

    September 2020
  234. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
    PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016